Resource for the Collection of Human Tissues, Cells, Biofluids and Epidemiologi

The National Cancer Institute (NCI) is seeking to modify its existing contract for the "Resource for the Collection and Evaluation of Human Tissues and Cells from Donors with an Epidemiology Profile" through a two-year extension of option periods. This specialized research and development contract involves the collection, storage, and evaluation of biological specimens including tissues, blood products, and swabs from cancer patients and population controls. The contractor must maintain strict privacy and ethical standards while characterizing tissue samples, providing epidemiological profiles using NCI-developed questionnaires, maintaining secure databases, abstracting medical records, and conducting survival searches. All work must comply with Institutional Review Board (IRB), HIPAA, and Federal Information Security Management Act (FISMA) regulations. The contracting agency plans to use FAR 6.302-1 single-source authority for this procurement, and interested parties must submit capability statements electronically to the Contracting Officer by July 15, 2025, at 12:00 PM EST.

This procurement does not utilize any set-aside designations and the current incumbent contractor is the University of Maryland, Baltimore, operating under contract number 75N91020C00007. The existing cost-reimbursement contract is valued at $7,053,827 and will be extended for two additional one-year option periods beginning September 30, 2025. The contract modification represents a continuation of ongoing biological specimen collection and research activities that support the National Cancer Institute's epidemiological research mission. The procurement falls under NAICS code 541715 for Research and Development in the Physical, Engineering, and Life Sciences, and PSC code AN11 for Health R&D Services and Basic Research. The extended contract periods will allow for sustained collection and analysis of human biological materials critical to cancer research initiatives.